P. Jänne

Publications682
h-index127
Citations74,761
Highly Influential Citations3,179
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Kris
  • 828 Publications • 72,503 Citations
  • G. Riely
  • 470 Publications • 51,115 Citations
  • M. Ladanyi
  • 866 Publications • 125,922 Citations
  • J. Engelman
  • 407 Publications • 65,117 Citations
  • Publications
  • Influence
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
TLDR
Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan. Expand
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
TLDR
It is proposed that MET amplification may promote drug resistance in other ERBB-driven cancers as well after it was found that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Expand
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
TLDR
The case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefItinib, where the DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Expand
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
TLDR
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy. Expand
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
TLDR
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects. Expand
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
TLDR
AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. Expand
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination…
TLDR
EGFR mutations may be a positive prognostic factor for survival in advanced NSCLC patients treated with chemotherapy with or without erlotinib, and may predict greater likelihood of response. Expand
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
TLDR
Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma. Expand
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
TLDR
Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC and there seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed. Expand
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
TLDR
Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy is highlighted. Expand
...
1
2
3
4
5
...